Patent Registration (Israel) for Redasemtide in Cartilage Disorders
Filed with TSE · · 2 pages · English
Summary by 6ix AI
StemRIM Inc. has announced the registration of a patent in Israel for the use of Redasemtide in treating cartilage disorders, including osteoarthritis and traumatic cartilage defects. This patent aims to expand the therapeutic indications for Redasemtide, which is currently under development. The company believes that this patent will facilitate the development of a drug for cartilage disorders in Israel. The financial impact of this patent registration for the fiscal year ending in the following year is expected to be insignificant.
Written by 6ix AI from the company’s filing. How 6ix writes summaries
Story so far
- Patent Registration in South Korea for Redasemtide in Cartilage Disorders
- StemRIM Announces Patent Registration (Mexico) for Redasemtide, as an Additional Therapeutic Indication of Cartilage Disorders
- StemRIM Announces Patent Registration (Canada) for Redasemtide, as an Additional Therapeutic Indication for Cardiomyopathy, Old Myocardial Infarction
Earlier from StemRIM
- Presentation Material for Business Plan and Growth Potential
- Notice Regarding US Patent Registration of SR-GT1 for Dystrophic Epidermolysis Bullosa
- Patent Registration in South Korea for Redasemtide in Cartilage Disorders
- StemRIM Announces Fixed Details of the Issuance of Stock Options to Employees
- StemRIM Announces Issuance of Stock Acquisition Rights as Stock Options to Employees
Later from StemRIM
All StemRIM news releasesFollow StemRIM into a list and get an email when it puts out news.
Follow StemRIM